APPIA BIO

Innovating Cell Therapy

 

TEAM

We collaborate across a diversity of disciplines, which is critical to developing next-generation therapies for patients.

 

OUR TECHNOLOGY

With our ACUA technology platform, Appia Bio leverages the biology of lymphocyte development with chimeric antigen receptor (CAR) and T-cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-iNKT) cell subtypes from hematopoietic stem cells (HSCs). Our research and development efforts are focused on engineered allogeneic cell therapies with a scalable technology platform to increase therapeutic options and availability for patients.

Pipetting Samples and Test Tube
 
Image by Nate Bell

MEDIA & PRESS UPDATES

 

APPIA BIO ANNOUNCES APPOINTMENT OF IRVING WEISSMAN, MD AND MARK EXLEY, PHD TO SCIENTIFIC ADVISORY BOARD

December 1, 2021

KITE AND APPIA BIO ANNOUNCE COLLABORATION FOR  ALLOGENEIC CELL THERAPIES FOR CANCER

August 5, 2021

APPIA BIO NAMES CELL THERAPY MANUFACTURING VETERAN QI WEI, PHD AS SENIOR VICE PRESIDENT OF TECHNICAL OPERATIONS

May 19, 2021

APPIA BIO LAUNCHES WITH $52 MILLION SERIES A FINANCING AND ESTABLISHES SCIENTIFIC ADVISORY BOARD

May 11, 2021

JOIN US

We’re a growing early-stage biotechnology company. We're looking for talented people who are passionate about innovating new medicines at the cutting-edge of science. See our job listings at: 

https://www.linkedin.com/company/appiabio/jobs/

6160 Bristol Parkway #300 Culver City, CA 90230